Ophthalmological events in patients receiving risedronate: Summary of information gained through follow-up in a prescription-event monitoring study in England

Drug Safety

Volumn 29, Issue 2, 2006, Pages 151-160

  Aurich Barrera, Beate ^a,b   Wilton, Lynda ^a,b   Harris, Scott ^a,c   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONJUNCTIVITIS; CONTROLLED STUDY; DIPLOPIA; DISEASE CLASSIFICATION; DRUG MONITORING; DRY EYE; EPISCLERITIS; EYE DISEASE; EYE INFLAMMATION; EYE PAIN; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HEMIANOPIA; HUMAN; IRITIS; KERATITIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ONSET AGE; OSTEOPOROSIS; PAGET BONE DISEASE; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; QUESTIONNAIRE; UNITED KINGDOM; VISUAL DISORDER; VISUAL FIELD DEFECT; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; ENGLAND; ETIDRONIC ACID; EYE DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG;

EID: 32244437347     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200629020-00005     Document Type: Article

References (44)

1. Actonel 5mg [summary of product characteristics]. Egham: Procter and Gamble Pharmaceuticals UK Ltd, 2002
2. Actonel 30mg [summary of product characteristics]. Egham: Procter and Gamble Pharmaceuticals UK Ltd, 2002
3. Actonel once a week 35mg [summary of product characteristics]. Egham: Procter and Gamble Pharmaceuticals UK Ltd, 2003
4. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11 (1): 83-91
5. Brown JP, Chines AA, Myers WR, et al. Improvement of pagetic bone lesions with risedronate treatment: a radiologic study. Bone 2000 Mar; 26 (3): 263-7
6. Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep 2003 Feb; 5 (1): 65-74
7. Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem 2004; 4 (7): 711-9
8. Fisher JE, Rodan GA, Reszka AA. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000 Dec; 141 (12): 4793-6
9. Rogers HL, Marshall D, Rogers MJ. Effects of Bisphosphonates on osteoclasts in vitro, studies by scanning electron microscopy. Bone 2002; 30: 435
10. Zhang D, Udagawa N, Nakamura I, et al. The small GTP-binding protein Rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci 1995; 108: 2285-92
11. Reszka AA, Halasy-Nagy JM, Masarachia PJ, et al. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis: a link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 1999 Dec 3; 274 (49): 34967-73
12. Sanders JM, Ghosh S, Chan JM, et al. Quantative structure-activity relationships for gammadelta T cell activation by biphosphonates. J Med Chem 2004; 47 (2): 375-84
13. Siris ES. Bisphosphonates and iritis. Lancet 1993; 341: 436-7
14. Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 2003; 135 (2): 219-22
15. Fraunfelder FW, Fraunfelder FT. Bisphosphonates and ocular inflammation. N Engl J Med 2003 Mar 20; 348 (12): 1187-8
16. Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994; 118 (2): 220-4
17. De S, Meyer P, Crisp AJ. Pamidronate and Uveitis. Br J Rheumatol 1995; 34 (5): 479
18. Mbekeani JN, Slamovits TL, Schwartz BH, et al. Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 1999 Jun; 117 (6): 837-8
19. O'Donnell N, Rao GP, Aguis-Fernandez A. Paget's disease: ocular complications of disodium pamidronate treatment. Br J Clin Pract 1995; 49 (5): 272-3
20. Rey J, Daumen-Legre V, Pham T, et al. Uveitis, an under-recognized adverse effect of pamidronate: case report and literature review. Joint Bone Spine 2000; 67 (4): 337-40
21. Salmen S, Berrueta L, Sanchez N, et al. Nongranulomatous anterior uveitis associated with alendronate therapy. Invest Clin 2002; 43 (1): 49-52
22. Asensio Sanchez VM, Botella Oltra G, Carrasco E. Bifosfonatos e inflamacion intraocular. Arch Soc Esp Oftalmol 2004; 2: 2-4
23. Malik AR, Campbell SH, Toma NM. Bilateral acute anterior uveitis after alendronate [letter]. Br J Ophthalmol 2002; 86 (12): 1443
24. Leung S, Ashar BII, Miller RG. Bisphosphonate-associated scleritis: a case report and review. South Med J 2005; 98 (7): 733-5
25. Fietta P, Manganelli P, Lodigiani L. Clodronate induced uveitis [letter]. Ann Rheum Dis 2003; 62 (4): 378
26. Durnian JM, Olujohungbe A, Kyle G. Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy. Eye 2005; 19 (2): 221-2
27. Haverbeke G, Pertile G, Claes C, et al. Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports. Bull Soc Belge Ophtamol 2003; (290): 71-6
28. Ghose K, Waterworth R, Trolove P, et al. Uveitis associated with pamidronate. Aust N Z J Med 1994; 24 (3): 320
29. Stewart GO, Stuckey BG, Ward LC, et al. Iritis following intravenous pamidronate. Aust N Z J Med 1996; 26 (3): 414-5
30. Vinas G, Olive A, Holgado S, et al. Episcleritis secondary to risedronate. Med Clin (Barc) 2002 Apr 27; 118 (15): 598-9
31. Barrera BA, Wilton L, Harris S, Shakir SA. Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England. Osteoporos Int 2005: Epub ahead of print
32. Shakir SAW. Prescription-event monitoring. In: BL Strom, editor. Pharmacoepidemiology. 4th ed. Chichester: John Wiley & Sons Ltd, 2005: 203-16
33. Shakir SA. Causality and correlation in pharmacovigilance. In: Talbot PW, editor. Stephens' detection of new adverse drug reactions. 5th ed. Chichester: John Wiley & Sons Ltd, 2004: 329-43
34. CIOMS.WHO. International Guidelines for Biomedical Research Involving Human Subjects. Geneva: CIOMS WHO, 1993
35. Multi-Centre Research Ethics Committee Guidance Notes. Examples of enquiries and surveys in the public interest where no reference to a Research Ethics Committee is necessary. UK, MREC, 2000; Appendix C:21
36. Guidelines on practice of ethical committees in medical research involving human subjects. Royal College of Physicians of London. August 1996
37. Heeley E, Riley J, Layton D, et al. Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2001 Dec 1; 358 (9296): 1872-3
38. McAvoy BR, Kramer EF. General practice postal surveys: a questionnaire too far? BMJ 1996 Sep 21; 313 (7059): 732-3
39. Biswas PN, Wilton LV, Shakir SA. Pharmacovigilance study of alendronate in England. Osteoporos Int 2003; 14 (6): 507-14
40. Springuel P, McMorran M. Biphosphonates and ocular disorders; Canadian Adverse Drug Reaction Newsletter. Canada: Health Canada, 2003: 1-2
41. Topliss D, Isaacs D, Lander C, et al. Bisphosphonates and ocular inflammation. Aust Adv Drug Reactions Bull 2004; 23 (2): 7-8
42. Reszka AA, Halasy-Nagy J, Rodan GA. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for oesophageal irritation. Mol Pharmacol 2001 Feb; 59 (2): 193-202
43. Santini D, Fratto ME, Vincenzi B, et al. Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cyutokine activities. BioDrugs 2004; 18 (4): 269-78
44. Nelson JD, Helms H, Fiscella R, et al. A new look at dry eye disease and its treatment. Adv Ther 2000; 17 (2): 84-93